A5034992947- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Immune cells in cancer
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Gastrointestinal Tumor Research and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Neutropenia and Cancer Infections
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Venous Thromboembolism Diagnosis and Management
- Immune Response and Inflammation
- Hematopoietic Stem Cell Transplantation
- Pharmaceutical studies and practices
- SARS-CoV-2 and COVID-19 Research
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Fungal Infections and Studies
Policlinico Universitario di Catania
2013-2025
Azienda Sanitaria di Firenze
2025
University of Catania
2010-2024
University of Asia and the Pacific
2023
University of Hassan II Casablanca
2023
Hôpital Européen Georges-Pompidou
2021
Assistance Publique – Hôpitaux de Paris
2021
Munich Leukemia Laboratory (Germany)
2016-2019
Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele
2014-2016
Ferrarotto Hospital
2010-2014
Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets patients lacking, especially relapsed or refractory leukemia.AVALON a multicentric cohort study that was conducted Italy AML who received venetoclax-based therapies from 2015 to 2020. The approved by ethics committee participating institution and accordance Declaration Helsinki. effectiveness toxicity venetoclax + HMA 190 (43 newly...
Summary In the attempt to find a peripheral blood biological marker that could mirror dysregulated microenvironment of Hodgkin Lymphoma ( HL ), we analysed amount myeloid‐derived suppressor cells MDSC including three main sub‐types (monocytic, granulocytic and CD 34 + fraction). The absolute count was investigated in 60 consecutive newly diagnosed patients correlated with clinical variables at diagnosis outcome. Patients received standard‐of‐care chemotherapy exception interim...
Patients affected by myelofibrosis (MF) or polycythemia vera (PV) and treated with ruxolitinib are at high risk for severe coronavirus disease 2019. Now a vaccine against the virus SARS-CoV-2, which is responsible this disease, available. However, sensitivity to vaccines usually lower in these patients. Moreover, fragile patients were not included large trials investigating efficacy of vaccines. Thus, little known about approach group In prospective single-center study, we evaluated 43 (30...
Abstract Acute myeloid leukemia (AML) with mutated NPM1 accounts for one-third of newly diagnosed AML. Despite recent advances, treatment relapsed/refractory -mutated AML remains challenging, the majority patients eventually dying due to disease progression. Moreover, prognosis is particularly poor in elderly and unfit patients, mainly because they cannot receive intensive treatment. Therefore, alternative strategies are needed. Dactinomycin a low-cost chemotherapeutic agent, which has been...
// Alessandra Romano 1 , Nunziatina Laura Parrinello Calogero Vetro Daniele Tibullo Cesarina Giallongo Piera La Cava Annalisa Chiarenza Giovanna Motta Anastasia L. Caruso Loredana Villari 2 Claudio Tripodo 3 Sebastiano Cosentino 4 Massimo Ippolito Ugo Consoli 5 Andrea Gallamini 6 Stefano Pileri 7 Francesco Di Raimondo Division of Hematology, AOU "Policlinico - Vittorio Emanuele", University Catania, Italy Pathology, Tumor Immunology Unit, Department Health Science, Palermo, Nuclear Medicine...
Azacytidine (5-AZA) is the standard first-choice treatment for high-risk myelodysplasia (MDS) patients. However, clinical outcome those patients who interrupt or whose disease failed to respond very poor. In order identify cellular pathways that are modified by long-term exposure 5-AZA, we evaluated key proteins associated with autophagy pathway reverse-phase microarray (RPPA). Comparing bone marrow mononucleated cells (BMMCs) obtained from 20 newly-diagnosed and after four 5-AZA cycles...
The wide use of ruxolitinib, approved for treating primary and secondary myelofibrosis (MF), has revolutionized the landscape these diseases. This molecule can reduce spleen volume constitutional symptoms, guaranteeing patients a better quality life survival or even valid bridge to bone marrow transplantation. Despite rapid response within first 3 6 months treatment, some fail achieve significant benefit lose early response. After ruxolitinib failure, new drugs are available provide an...
In the last decades, evaluation of clinically relevant thrombotic complications in patients with acute leukemia (AL) has been poorly investigated. The authors performed a multi-center study to evaluate management symptomatic venous thromboembolism (VTE) adult AL. intention was find as following: Venous Thrombosis (VT) occurred typical (lower limbs) and atypical (cerebral, upper limbs, abdominal, etc) sites or without pulmonary embolism (PE). Over population 1461 AL, 22 cases VTE were...